Neuromodulation to Reduce Muscle Stiffness Following Spinal Cord Injury
Public ClinicalTrials.gov record NCT06274021. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Shared and Distinct Antispastic Effects of Electrical and Pharmacological Neuromodulation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
People with spinal cord injuries may experience muscle tightness or uncontrollable spasms. This study is being conducted to investigate whether transcutaneous spinal stimulation can improve these symptoms. Transcutaneous spinal stimulation is a non-surgical intervention by applying electrical currents using skin electrodes over the lower back and belly. The investigators want to see how well the intervention of transcutaneous spinal stimulation performs by testing different levels of stimulation pulse rates. Also, transcutaneous spinal stimulation is compared to muscle relaxants such as baclofen and tizanidine, commonly given to people with spinal cord injuries, to reduce muscle stiffness and spasms. By doing this, the investigators hope to discover if transcutaneous spinal stimulation similarly reduces muscle spasms and stiffness or if combining both methods works best. This could help improve treatment options for people with spinal cord injuries in the future.
Study identification
- NCT ID
- NCT06274021
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Early Phase 1
- Enrollment
- 16 participants
Conditions and interventions
Conditions
Interventions
- Transcutaneous spinal stimulation at 100 Hz Device
- Transcutaneous spinal stimulation at 50 Hz Device
- Transcutaneous spinal stimulation at 50 Hz and single dose of baclofen Combination Product
- Transcutaneous spinal stimulation at 50 Hz and single dose of tizanidine Combination Product
- Sham transcutaneous spinal stimulation Device
Device · Combination Product
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 29, 2024
- Primary completion
- Dec 30, 2025
- Completion
- Dec 30, 2025
- Last update posted
- Jun 30, 2024
2024 – 2025
United States locations
- U.S. sites
- 2
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Methodist Rehabilitation Center | Jackson | Mississippi | 39216 | Recruiting |
| University of Mississippi Medical Center | Jackson | Mississippi | 39216 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06274021, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 30, 2024 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06274021 live on ClinicalTrials.gov.